• 1. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 2. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 3. Dissociation of large gaseous serine clusters produces abundant protonated serine octamer
  Jacob S. Jordan,Evan R. Williams Analyst, 2021,146, 2617-2625
• 4. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 5. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466

Professional Introduction to Compound with CAS No. 1553247-60-1 and Product Name: 3-(2-Ethylbutoxy)azetidine

The compound with the CAS number 1553247-60-1 and the product name 3-(2-Ethylbutoxy)azetidine represents a significant advancement in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique structural framework, has garnered considerable attention due to its potential applications in drug development and molecular recognition. The azetidine ring, a five-membered heterocyclic structure, is particularly noteworthy for its versatility in forming stable complexes with various biological targets. The presence of the 2-Ethylbutoxy moiety further enhances its pharmacological profile, making it a promising candidate for further investigation.

In recent years, the pharmaceutical industry has witnessed a surge in the exploration of heterocyclic compounds due to their diverse biological activities. Among these, azetidine derivatives have emerged as key scaffolds in the design of novel therapeutic agents. The compound 3-(2-Ethylbutoxy)azetidine exemplifies this trend, offering a unique combination of structural features that could contribute to its efficacy in modulating biological pathways. Specifically, the azetidine ring is known for its ability to interact with enzymes and receptors, which is crucial for developing drugs that target specific diseases.

One of the most compelling aspects of 3-(2-Ethylbutoxy)azetidine is its potential role in inhibiting enzymes that are involved in inflammatory processes. Inflammatory responses are central to numerous diseases, including autoimmune disorders and chronic inflammatory conditions. By targeting these enzymes, compounds like 3-(2-Ethylbutoxy)azetidine could offer a new avenue for therapeutic intervention. Recent studies have highlighted the importance of azetidine derivatives in modulating inflammatory pathways, particularly through their interaction with cyclooxygenase (COX) enzymes. These enzymes are key players in the production of prostaglandins, which are mediators of inflammation.

Furthermore, the 2-Ethylbutoxy group in 3-(2-Ethylbutoxy)azetidine contributes to its pharmacokinetic properties, enhancing both solubility and bioavailability. This feature is particularly important for drug development, as it ensures that the compound can be effectively absorbed and distributed throughout the body. Improved bioavailability often translates to higher therapeutic efficacy, making 3-(2-Ethylbutoxy)azetidine a promising candidate for clinical trials.

Recent advancements in computational chemistry have also played a pivotal role in understanding the molecular interactions of 3-(2-Ethylbutoxy)azetidine. Molecular docking studies have revealed that this compound can bind to various biological targets with high affinity. For instance, simulations have shown that it can interact with COX-1 and COX-2 enzymes, suggesting potential applications in pain management and anti-inflammatory therapies. Additionally, its ability to bind to other enzymes and receptors has implications for treating a wide range of diseases beyond inflammation.

The synthesis of 3-(2-Ethylbutoxy)azetidine represents another area of interest within the chemical community. Researchers have developed novel synthetic routes that improve yield and purity while minimizing side reactions. These advancements are crucial for scaling up production and making the compound more accessible for further research. The synthetic strategies employed also provide insights into how other azetidine derivatives can be synthesized, fostering innovation in medicinal chemistry.

In conclusion, 3-(2-Ethylbutoxy)azetidine (CAS No. 1553247-60-1) is a compound with significant potential in pharmaceutical research. Its unique structural features, combined with its ability to interact with key biological targets, make it a valuable tool for developing new therapeutic agents. As research continues to uncover more about its properties and applications, it is likely that this compound will play an increasingly important role in addressing various medical challenges.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)